62 related articles for article (PubMed ID: 36911986)
1. Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With
Liu Y; Li Y; Xu H; Zhou L; Yang X; Wang C
Int J Surg Pathol; 2023 Dec; 31(8):1485-1494. PubMed ID: 36911986
[TBL] [Abstract][Full Text] [Related]
2. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
[TBL] [Abstract][Full Text] [Related]
3. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
[TBL] [Abstract][Full Text] [Related]
4. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma.
Chakiryan NH; Hajiran A; Kim Y; Aydin AM; Zemp L; Katende E; Nguyen J; Fan W; Cheng CH; Lopez-Blanco N; Chahoud J; Spiess PE; Fournier M; Dhillon J; Wang L; Moran-Segura C; Mulé J; Du D; Yoder SJ; Berglund A; Teer JK; Manley BJ
Eur Urol Focus; 2022 May; 8(3):784-793. PubMed ID: 33994165
[TBL] [Abstract][Full Text] [Related]
5. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.
Farley MN; Schmidt LS; Mester JL; Pena-Llopis S; Pavia-Jimenez A; Christie A; Vocke CD; Ricketts CJ; Peterson J; Middelton L; Kinch L; Grishin N; Merino MJ; Metwalli AR; Xing C; Xie XJ; Dahia PLM; Eng C; Linehan WM; Brugarolas J
Mol Cancer Res; 2013 Sep; 11(9):1061-1071. PubMed ID: 23709298
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.
Rosellini M; Mollica V; Marchetti A; Coluccelli S; Giunchi F; Tassinari E; Ricci C; Fiorentino M; Tallini G; De Biase D; Massari F
Pathol Res Pract; 2024 Feb; 254():155142. PubMed ID: 38277752
[TBL] [Abstract][Full Text] [Related]
7. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
Manley BJ; Zabor EC; Casuscelli J; Tennenbaum DM; Redzematovic A; Becerra MF; Benfante N; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Ogawa S; Arcila ME; Voss MH; Feldman DR; Coleman JA; Reuter VE; Motzer RJ; Russo P; Hsieh JJ; Hakimi AA
Eur Urol Focus; 2017 Oct; 3(4-5):421-427. PubMed ID: 28753773
[TBL] [Abstract][Full Text] [Related]
8. Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA-RCC) Imaging Research Group.
Shinagare AB; Vikram R; Jaffe C; Akin O; Kirby J; Huang E; Freymann J; Sainani NI; Sadow CA; Bathala TK; Rubin DL; Oto A; Heller MT; Surabhi VR; Katabathina V; Silverman SG
Abdom Imaging; 2015 Aug; 40(6):1684-92. PubMed ID: 25753955
[TBL] [Abstract][Full Text] [Related]
9. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Ricketts CJ; De Cubas AA; Fan H; Smith CC; Lang M; Reznik E; Bowlby R; Gibb EA; Akbani R; Beroukhim R; Bottaro DP; Choueiri TK; Gibbs RA; Godwin AK; Haake S; Hakimi AA; Henske EP; Hsieh JJ; Ho TH; Kanchi RS; Krishnan B; Kwiatkowski DJ; Liu W; Merino MJ; Mills GB; Myers J; Nickerson ML; Reuter VE; Schmidt LS; Shelley CS; Shen H; Shuch B; Signoretti S; Srinivasan R; Tamboli P; Thomas G; Vincent BG; Vocke CD; Wheeler DA; Yang L; Kim WY; Robertson AG; ; Spellman PT; Rathmell WK; Linehan WM
Cell Rep; 2018 Apr; 23(1):313-326.e5. PubMed ID: 29617669
[TBL] [Abstract][Full Text] [Related]
10. The Prevalence and Radiologic Features of Renal Cancers Associated with
Charbel C; Causa Andrieu PI; Soliman M; Woo S; Zheng J; Capanu M; Nikolovski I; Vargas HA; Abusamra M; Carlo MI
Radiol Imaging Cancer; 2024 Mar; 6(2):e230063. PubMed ID: 38456787
[TBL] [Abstract][Full Text] [Related]
11. Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma.
Wei X; Choudhury Y; Lim WK; Anema J; Kahnoski RJ; Lane B; Ludlow J; Takahashi M; Kanayama HO; Belldegrun A; Kim HL; Rogers C; Nicol D; Teh BT; Tan MH
Sci Rep; 2017 Aug; 7(1):7342. PubMed ID: 28779136
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Genomic Features of Patients with Renal Cell Carcinoma and Advanced Chronic Kidney Disease: Analysis of a Multi-Institutional Database.
Eule CJ; Hu J; Hedges D; Jani A; Pshak T; Manley BJ; Sanchez A; Dreicer R; Myint ZW; Zakharia Y; Lam ET
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791999
[TBL] [Abstract][Full Text] [Related]
13. Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma.
Xu Z; Jiang W; Liu L; Qiu Y; Wang J; Dai S; Guo J; Xu J
Cancer Immunol Immunother; 2024 Apr; 73(5):95. PubMed ID: 38607586
[TBL] [Abstract][Full Text] [Related]
14. Aggressive renal cell carcinoma with biphasic papillary and solid clear cell features harboring IDH2 (R172M) mutation.
Zhao M; Xia Y; Wang W
Pathol Res Pract; 2024 Jan; 253():155090. PubMed ID: 38181579
[TBL] [Abstract][Full Text] [Related]
15. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.
Dalgliesh GL; Furge K; Greenman C; Chen L; Bignell G; Butler A; Davies H; Edkins S; Hardy C; Latimer C; Teague J; Andrews J; Barthorpe S; Beare D; Buck G; Campbell PJ; Forbes S; Jia M; Jones D; Knott H; Kok CY; Lau KW; Leroy C; Lin ML; McBride DJ; Maddison M; Maguire S; McLay K; Menzies A; Mironenko T; Mulderrig L; Mudie L; O'Meara S; Pleasance E; Rajasingham A; Shepherd R; Smith R; Stebbings L; Stephens P; Tang G; Tarpey PS; Turrell K; Dykema KJ; Khoo SK; Petillo D; Wondergem B; Anema J; Kahnoski RJ; Teh BT; Stratton MR; Futreal PA
Nature; 2010 Jan; 463(7279):360-3. PubMed ID: 20054297
[TBL] [Abstract][Full Text] [Related]
16. SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma.
Liu XD; Zhang YT; McGrail DJ; Zhang X; Lam T; Hoang A; Hasanov E; Manyam G; Peterson CB; Zhu H; Kumar SV; Akbani R; Pilie PG; Tannir NM; Peng G; Jonasch E
Clin Cancer Res; 2023 Oct; 29(19):4002-4015. PubMed ID: 37527013
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma.
Wu Y; Terekhanova NV; Caravan W; Naser Al Deen N; Lal P; Chen S; Mo CK; Cao S; Li Y; Karpova A; Liu R; Zhao Y; Shinkle A; Strunilin I; Weimholt C; Sato K; Yao L; Serasanambati M; Yang X; Wyczalkowski M; Zhu H; Zhou DC; Jayasinghe RG; Mendez D; Wendl MC; Clark D; Newton C; Ruan Y; Reimers MA; Pachynski RK; Kinsinger C; Jewell S; Chan DW; Zhang H; Chaudhuri AA; Chheda MG; Humphreys BD; Mesri M; Rodriguez H; Hsieh JJ; Ding L; Chen F
Nat Commun; 2023 Mar; 14(1):1681. PubMed ID: 36973268
[TBL] [Abstract][Full Text] [Related]
18. Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma.
Cotta BH; Choueiri TK; Cieslik M; Ghatalia P; Mehra R; Morgan TM; Palapattu GS; Shuch B; Vaishampayan U; Van Allen E; Ari Hakimi A; Salami SS
Eur Urol; 2023 Aug; 84(2):166-175. PubMed ID: 37085424
[TBL] [Abstract][Full Text] [Related]
19. Reconstruction of kidney renal clear cell carcinoma evolution across pathological stages.
Pang S; Sun Y; Wu L; Yang L; Zhao YL; Wang Z; Li Y
Sci Rep; 2018 Feb; 8(1):3339. PubMed ID: 29463849
[TBL] [Abstract][Full Text] [Related]
20. PBRM1 bromodomains associate with RNA to facilitate chromatin association.
De Silva SM; Dhiman A; Sood S; Mercedes KF; Simmons WJ; Henen MA; Vögeli B; Dykhuizen EC; Musselman CA
Nucleic Acids Res; 2023 May; 51(8):3631-3649. PubMed ID: 36808431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
